Increasing patient Population to Boost the Global Biologic Therapy Market During the Forecast Period

The biologic therapy market is estimated to register a CAGR of 9.3% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global biologic therapy market Samsung Biologics (South Korea), Amgen Inc (US), Novo Nordisk A/S (Denmark), Sanofi (France), Johnson & Johnson Services, Inc (US), Celltrion Healthcare Co., Ltd (South Korea), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann La-Roche Ltd (Switzerland), Aeglea BioTherapuetics (US) and others.

Biologic Therapy Market Highlights

The global biologic therapy market is accounted for to register a CAGR of 9.3% during the forecast period and is estimated to reach USD 998.36 billion by 2032.

The single largest growth trend is the increasing cancer prevalence across the globe. The market space witnesses increasing advancements in biomedical science across the globe which drives the growth of the biologic therapy market. In addition, there is an increasing need for better therapeutic treatment. One such key growth factor promoting an exponential increase in Year on Year (%) growth due to the rising pipeline of products is driving the growth of the biologic therapy market.

Furthermore, the growing number of product approvals propels the growth of biologic therapy market. However, increasing the cost of treatment is expected to hamper the growth of the global market. Nevertheless, the growing preference of biologic therapy is projected to create lucrative opportunity pockets for market players. We estimate a more focused business initiates targeting the same would result in greater revenue pockets for market players.

Access full details on Biologic Therapy Market Research Report

Segment Analysis

The global biologic therapy market is segmented into product type, therapy, application, and end user. The product type segment is further sub segmented into drugs, instruments & kits, services. The drugs segment was attributed to holding the largest market share in 2022 with a market share of 80% as estimated by MRFR analysts.

The drugs provide better therapeutic effect and increasing number of clinical trial ongoing in development of new therapeutics in biologic therapy is driving market growth. The segment is also expected to grow at the fastest CAGR owing to the increasing product approvals. It has been identified that the segment market yet witnesses continuously increasing research and development activity and product launches.  For instance, It is also strongly backed by the increasing collaborations to innovate effective biologics.

Further, based on therapy, the market is segmented into monoclonal antibodies, vaccines, others. based on application, the market is segmented into cancer, infectious diseases, autoimmune diseases, and others. based on end user, the market is segmented into hospitals & clinics, specialty centers, research centers.

Regional Analysis

The global biologic therapy market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.

The biologic therapy market for North America is analyzed across US and Canada. US accounted for a major share of the biologic therapy market in 2022 and is expected to maintain its lead during the forecast period, due to the increasing product approvals, highly investment in research and development activities by the market players and, increasing incidence of cancer in the US. For instance: National Institute of Health, around 1,898,160 new cases reported of cancer in the US in 2021.

Moreover, the Europe market has been persistently growing owing to factors such as the increasing research and development activity, growing number of clinical trials. The rising presence of major key players in the market, increasing incidence of neurologic disease in the Europe region drive the growth of biologic therapy market in the Europe.

Additionally, market factors, such as epidemiology factor, increasing investment by foreign companies in the emerging economies, rising out of packet expenditure, developing economy drive the growth of biologic therapy market in the Asia-Pacific region.

 Furthermore, the rest of the world's market is divided into the Middle East, Africa, and Latin America. The market factors such as the increasing government support, rising the demand of better medical treatment market across the region which drive the growth of the market. This is expected to bolster the market for biologic therapy in this region across the region and further boost the growth of the market.

Key Findings of the Study

• The global biologic therapy market is expected to reach USD 998.36 billion by 2032, at a CAGR of 9.32% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, the increasing investment by foreign companies in the emerging economies, rising out of packet expenditure, developing research infrastructure drive the growth of biologic therapy market in Asia-Pacific region.


• Based on product type, the drugs segment was attributed to holding the largest market in 2022, with an approximate market share of 81.1%.


• Samsung Biologics (South Korea), Amgen Inc (US), Novo Nordisk A/S (Denmark), Sanofi (France), Johnson & Johnson Services, Inc (US), Celltrion Healthcare Co., Ltd (South Korea), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann La-Roche Ltd (Switzerland), Aeglea BioTherapuetics (US), and others.